Panelists discuss how airway clearance devices and techniques, including chest physical therapy, active cycle breathing, ...

Panelists discuss how evaluating potential causes of bronchiectasis is important despite many cases being idiopathic, as ...

The drug is manufactured by the US firm Insmed and made possible after 15 years of research by scientists from the University ...

Good afternoon, and thank you for joining the Electromed earnings call. Earlier today, Electromed, Inc. released financial results for the third fiscal quarter of 2025, the quarter ended March 31, ...

Gross profit rose to $12.2 million, representing 78.0% of net revenues. Selling, general, and administrative expenses were $9.8 million, a 17.2% increase. Operating income was $2.1 million, net income ...

The world’s first potential therapy for an increasingly common, chronic lung condition has been identified following a trial ...

British scientists have developed a world-first treatment for an incurable condition that contributed to the Pope’s death.

Q1 2025 Earnings Call Transcript May 8, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.42 EPS, ...

Learn more about whether Exact Sciences Corporation or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups - read more about the latest trial ...

Researchers have discovered in a new study that treating airway inflammation with the experimental drug brensocatib lowers ...

Advance physiotherapy itself through publication of research and scholarly work concerned with, but not limited to, its scientific basis and clinical application, education of practitioners, ...